Amneal Pharmaceuticals (NYSE:AMRX) updated its FY 2019 earnings guidance on Thursday. The company provided earnings per share guidance of $0.94-1.04 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.24. Amneal Pharmaceuticals also updated its FY19 guidance to $0.94-1.04 EPS.
A number of brokerages have issued reports on AMRX. Morgan Stanley lowered shares of Amneal Pharmaceuticals from an overweight rating to an equal weight rating and decreased their target price for the stock from $24.00 to $18.00 in a research report on Friday, December 14th. Leerink Swann restated an outperform rating and set a $19.00 target price (down previously from $25.00) on shares of Amneal Pharmaceuticals in a research report on Thursday, January 3rd. Zacks Investment Research lowered shares of Amneal Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, January 8th. Cantor Fitzgerald restated a buy rating and set a $35.00 target price on shares of Amneal Pharmaceuticals in a research report on Thursday. Finally, ValuEngine lowered shares of Amneal Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday, January 10th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $21.67.
Shares of NYSE AMRX traded up $0.11 during trading hours on Friday, hitting $13.64. 31,963 shares of the stock were exchanged, compared to its average volume of 1,005,203. The company has a current ratio of 1.91, a quick ratio of 1.26 and a debt-to-equity ratio of 2.92. The firm has a market capitalization of $4.04 billion, a price-to-earnings ratio of 21.70, a P/E/G ratio of 0.51 and a beta of 1.38. Amneal Pharmaceuticals has a 1-year low of $11.66 and a 1-year high of $24.48.
Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings results on Thursday, February 28th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.06. Amneal Pharmaceuticals had a negative net margin of 36.54% and a positive return on equity of 4.98%. On average, equities research analysts forecast that Amneal Pharmaceuticals will post 0.9 earnings per share for the current year.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Further Reading: No Load Funds
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.